NOW ENROLLING PHASE III sunRIZE TRIAL In the study of congenital hyperinsulinism

Learn More »
sunrize logo

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

Back to Careers

Stay Connected

Email Alerts Contacts RSS News Feed
MENU